IMU Stock Overview
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia.
Imugene Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.046|
|52 Week High||AU$0.21|
|52 Week Low||AU$0.046|
|1 Month Change||-30.30%|
|3 Month Change||-49.45%|
|1 Year Change||-74.44%|
|3 Year Change||-9.80%|
|5 Year Change||109.09%|
|Change since IPO||-52.82%|
Recent News & Updates
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn SituationSep 19
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn RateMay 30
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth PlansJan 30
Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little MoreNov 11
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth PlansAug 22
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn SituationFeb 28
A Look At Imugene's (ASX:IMU) CEO RemunerationFeb 17
Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five YearsDec 24
|IMU||AU Biotechs||AU Market|
Return vs Industry: IMU underperformed the Australian Biotechs industry which returned -11.4% over the past year.
Return vs Market: IMU underperformed the Australian Market which returned 5.9% over the past year.
|IMU Average Weekly Movement||10.6%|
|Biotechs Industry Average Movement||10.9%|
|Market Average Movement||8.4%|
|10% most volatile stocks in AU Market||15.8%|
|10% least volatile stocks in AU Market||3.1%|
Stable Share Price: IMU is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: IMU's weekly volatility (11%) has been stable over the past year.
About the Company
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in phase 2 study for gastric cancer.
Imugene Limited Fundamentals Summary
|IMU fundamental statistics|
Is IMU overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IMU income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
|Earnings per share (EPS)||-0.0055|
|Net Profit Margin||-372.30%|
How did IMU perform over the long term?See historical performance and comparison